Bioequivalence, AUC, Cmax, Pharmacokinetics
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 2 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
AstraZenecaCAMBRIDGE, United Kingdom
2 programs2
ClopidogrelPhase 11 trial
OmeprazolePhase 1Small Molecule1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
GEROPHARMMemantinol tablets, 20 mg
AstraZenecaClopidogrel
AstraZenecaOmeprazole
Clinical Trials (3)
Total enrollment: 216 patients across 3 trials
Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects
Start: Oct 2016Est. completion: Nov 201618 patients
Phase 1Completed
Clopidogrel Bioequivalence Study in Healthy Subjects
Start: Aug 2014Est. completion: Oct 2014144 patients
Phase 1Completed
Prilosec Bioequivalence Study in Healthy Volunteers
Start: Aug 2013Est. completion: Nov 201354 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.